DE:PBN Stock Latest News
Company AnnouncementsAlterity Therapeutics Secures FDA Alignment and New Patent as ATH434 Advances Toward Phase 33d ago
Company AnnouncementsAlterity Therapeutics Plans New ASX Option Issue to Bolster Capital Structure1w ago
Company AnnouncementsAlterity Therapeutics Issues New Unlisted Employee Options1w ago- Company AnnouncementsAlterity Therapeutics Grants New Unlisted Employee Options1w ago
Company AnnouncementsAlterity Therapeutics Sets Hybrid 2026 AGM, Urges Early Proxy Voting1w ago
Company AnnouncementsAlterity Therapeutics Updates CEO Remuneration as Neurodegeneration Programs Advance1w agoCompany AnnouncementsAlterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference3w ago
Company AnnouncementsAlterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial4w ago
Company AnnouncementsAlterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline1M ago
Company AnnouncementsAlterity Flags Development Risks Around Lead Neurodegeneration Drug ATH4341M ago- Company AnnouncementsAlterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference1M ago
Company AnnouncementsAlterity Therapeutics Seeks Quotation for New ASX Shares1M ago
Company AnnouncementsAlterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal1M ago
Company AnnouncementsAlterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares1M ago
Company AnnouncementsAlterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference2M ago
Company AnnouncementsAlterity Therapeutics Updates Director Equity Holdings After Option Expiry2M ago